Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hassle-free stroke prevention offered by new drug, Stanford researcher says

21.11.2003


People who take a commonly prescribed yet problematic drug called Coumadin to prevent stroke or blood clots may soon have a hassle-free alternative, according to research at Stanford University School of Medicine. Results from a 7,329-person international study have found that a new drug called ximelegatran prevents strokes as effectively as Coumadin without the side effects or inconvenience.



"We think this will result in a huge shift in anti-coagulation therapy," said Gregory Albers, MD, professor of neurology and neurological sciences and director of the Stanford Stroke Center. Albers was a member of the steering committee that designed and directed the trial. Results from the 3,407-person international phase of the study will be published in the Nov. 22 issue of The Lancet. Albers and his colleagues presented results from the 3,922-person North American study at the American Heart Association meeting Nov. 11 in Orlando.

Coumadin effectively thins the blood and prevents strokes in people with a type of erratic heartbeat called atrial fibrillation. The problem is that the drug has a very narrow effective dose range – too little and it doesn’t work, too much and a person bleeds excessively. The drug also interacts with other medications and with food. Because of these complications, people on Coumadin must have their blood checked and dose adjusted regularly to make sure they are protected from stroke.


"Coumadin is very effective, but more than half of the people who should be receiving it don’t take the medication because of the inconvenience," Albers said.

In contrast, ximelegatran is just as effective as Coumadin but doesn’t require blood tests for dose adjustment and doesn’t interact with medications or food. "It’s essentially one-dose-fits-all," Albers said.

Called the Stroke Prevention Using an Oral Thrombin Inhibitor in Atrial Fibrillation, or SPORTIF, the studies comparing ximelegatran to Coumadin took place in 25 countries. They included 7,329 patients who were treated with one of the two drugs for an average of nearly two years. These were the largest trials ever conducted on people with atrial fibrillation, Albers said.

During the trials, people in the two groups had similar rates of stroke or death, though those taking ximelegatran had fewer major bleeding incidents. Albers said the most important difference was that patients on Coumadin required constant dose adjustment while those on ximelegatran took the same dose throughout the trial.

Albers said that about 6 percent of people on ximelegatran had elevated levels of liver enzymes in the period between two to six months of treatment. This side effect usually disappeared without any consequences, but he said people on ximelegatran will need to have their liver function monitored during the first few months of therapy.

Albers said he expects ximelegatran to be approved by the U.S. Food and Drug Administration within the next year. It will be sold by the pharmaceutical company AstraZeneca under the brand name Exanta. Albers served as a consultant for AstraZeneca during the trial.


Stanford University Medical Center integrates research, medical education and patient care at its three institutions – Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital at Stanford. For more information, please visit the Web site of the medical center’s Office of Communication & Public Affairs at http://mednews.stanford.edu.

Amy Adams | EurekAlert!
Further information:
http://mednews.stanford.edu

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>